Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv
- 30 April 2010
- journal article
- Published by Elsevier BV in Experimental and Molecular Pathology
- Vol. 88 (2), 238-249
- https://doi.org/10.1016/j.yexmp.2010.01.006
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicityBlood, 2009
- Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)Investigational New Drugs, 2009
- Therapeutic Antibodies: Current State and Future Trends – Is a Paradigm Change Coming Soon?Published by Springer Science and Business Media LLC ,2008
- An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopesProceedings of the National Academy of Sciences of the United States of America, 2008
- HER2-Specific Affibody-Conjugated Thermosensitive Liposomes (Affisomes) for Improved Delivery of Anticancer AgentsJournal of Liposome Research, 2008
- Targeted pharmaceutical nanocarriers for cancer therapy and imagingThe AAPS Journal, 2007
- Eradication of Tumor Colonization and Invasion by a B Cell–Specific Immunotoxin in a Murine Model for Human Primary Intraocular LymphomaCancer Research, 2006
- Biosynthetically lipid‐modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomesFEBS Letters, 1996
- The role of multivalency in antibody mediated liposome targetingBiochemical and Biophysical Research Communications, 1987
- Carbamyl analogs of phosphatidylcholines: Synthesis, interaction with phospholipases and permeability behavior of their liposomesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1981